GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
GRAIL will present eight abstracts spanning the NHS-Galleri trial and PATHFINDER 2 study at the Early Detection of Cancer Conference (Oct. 6-8, Edinburgh) and ESMO Congress 2026 (Oct. 23-27, Madrid). Data include a rapid oral on safety and efficiency of Cancer Signal Origin-guided diagnostic workups, plus posters on detection of more than 200 cancers, performance across racial and ethnic groups, and reduced emergency-setting cancer diagnoses with annual Galleri screening.
Key figures
- Drug Name
- Galleri MCED test
- Cso accuracy
- greater than 90%
- Abstracts edcc
- 6
- Abstracts esmo
- 2
- Cancers screened
- more than 50 cancer types
- Stage iv reduction
- more than 20% after first year of screening
- Clinical program participants
- more than 380,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.